Ekyalongo RC - Search Results

1

Organization and functions of glycolipid-enriched microdomains in phagocytes.

Ekyalongo RC, Nakayama H, Kina K, Kaga N, Iwabuchi K. Ekyalongo RC, et al. Biochim Biophys Acta. 2015 Jan;1851(1):90-7. doi: 10.1016/j.bbalip.2014.06.009. Epub 2014 Jun 23. Biochim Biophys Acta. 2015. PMID: 24968752 Review.

2

Direct interaction, instrumental for signaling processes, between LacCer and Lyn in the lipid rafts of neutrophil-like cells.

Chiricozzi E, Ciampa MG, Brasile G, Compostella F, Prinetti A, Nakayama H, Ekyalongo RC, Iwabuchi K, Sonnino S, Mauri L. Chiricozzi E, et al. Among authors: ekyalongo rc. J Lipid Res. 2015 Jan;56(1):129-41. doi: 10.1194/jlr.M055319. Epub 2014 Nov 23. J Lipid Res. 2015. PMID: 25418321 Free PMC article.

3

Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.

Funakoshi Y, Mukohara T, Ekyalongo RC, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Funakoshi Y, et al. Among authors: ekyalongo rc. Oncol Res. 2013;21(6):287-93. doi: 10.3727/096504014X13946388748956. Oncol Res. 2013. PMID: 25198658

4

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.

Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y, Minami H. Tomioka H, et al. Among authors: ekyalongo rc. Int J Oncol. 2012 Aug;41(2):551-8. doi: 10.3892/ijo.2012.1485. Epub 2012 May 17. Int J Oncol. 2012. PMID: 22614071

5

Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

Ekyalongo RC, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N, Fujiwara Y, Minami H. Ekyalongo RC, et al. Invest New Drugs. 2013 Apr;31(2):293-303. doi: 10.1007/s10637-012-9855-1. Epub 2012 Jul 25. Invest New Drugs. 2013. PMID: 22828916

6

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Funakoshi Y, et al. Among authors: ekyalongo rc. Invest New Drugs. 2013 Oct;31(5):1158-68. doi: 10.1007/s10637-013-9959-2. Epub 2013 Apr 9. Invest New Drugs. 2013. PMID: 23568717

7

TYRO3 as a potential therapeutic target in breast cancer.

Ekyalongo RC, Mukohara T, Funakoshi Y, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Minami H. Ekyalongo RC, et al. Anticancer Res. 2014 Jul;34(7):3337-45. Anticancer Res. 2014. PMID: 24982338

8

SELENOF is a new tumor suppressor in breast cancer.

Zigrossi A, Hong LK, Ekyalongo RC, Cruz-Alvarez C, Gornick E, Diamond AM, Kastrati I. Zigrossi A, et al. Among authors: ekyalongo rc. Oncogene. 2022 Feb;41(9):1263-1268. doi: 10.1038/s41388-021-02158-w. Epub 2022 Jan 27. Oncogene. 2022. PMID: 35082382

9

Revisiting the IGF-1R as a breast cancer target.

Ekyalongo RC, Yee D. Ekyalongo RC, et al. NPJ Precis Oncol. 2017;1:14. doi: 10.1038/s41698-017-0017-y. Epub 2017 May 1. NPJ Precis Oncol. 2017. PMID: 29152592 Free PMC article.

10

SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells.

Ekyalongo RC, Flowers B, Sharma T, Zigrossi A, Zhang A, Quintanilla-Arteaga A, Singh K, Kastrati I. Ekyalongo RC, et al. Cancers (Basel). 2023 Jul 19;15(14):3671. doi: 10.3390/cancers15143671. Cancers (Basel). 2023. PMID: 37509331 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page